Lhasa Limited shared knowledge shared progress
Loading...

Publications

Jump to results
Authors
Publication Type
Publication Year
Related Products
Reset
New search
TitlePublishedTypeProducts
Session 3 - Exploiting AOPs as a framework to support ICH S1 risk assessments - SlidesOctober 2020pdf file
Session 3 - Exploiting AOPs as a framework to support ICH S1 risk assessments - RecordingOctober 2020
Session 3 - A pharmaceutical regulator’s view on the utility of adverse outcome pathways for carcinogenicity assessment - SlidesOctober 2020pdf file
Session 3 - A pharmaceutical regulator’s view on the utility of adverse outcome pathways for carcinogenicity assessment - RecordingOctober 2020
Fragrance Database 2020.2.0 Release NotesOctober 2020pdf fileVitic Nexus
Session 2 - Integration of adverse outcome pathways with experimental data to support the assessment of carcinogenic risk - SlidesOctober 2020pdf fileKaptis
Session 2 - Integration of adverse outcome pathways with experimental data to support the assessment of carcinogenic risk - RecordingOctober 2020Kaptis
Session 2 - AOP and IATA complimentary frameworks to modernize chemical risk assessment - SlidesOctober 2020pdf file
Session 2 - AOP and IATA complimentary frameworks to modernize chemical risk assessment - RecordingOctober 2020
Could purge calculations support your regulatory submissions? (Infographic)October 2020pdf fileMirabilis
Session 1 - Creating a DART AOP network to enable improved decision-making during risk assessments - RecordingOctober 2020
Session 1 - Creating a DART AOP network to enable improved decision-making during risk assessments - SlidesOctober 2020pdf file
Session 1 - Building quantitative AOPs of the DARTable genome to explore risks of developmental toxicity - SlidesOctober 2020pdf file
Session 1 - Building quantitative AOPs of the DARTable genome to explore risks of developmental toxicity - RecordingOctober 2020
Linking Evidence With AOPs To Produce Integrated Approaches to Testing and Assessment (IATA)September 2020pdf fileKaptis
Developing Federated QSAR Models for Secondary PharmacologySeptember 2020pdf file
The importance of expert review to clarify ambiguous situations for (Q)SAR predictions under ICH M7September 2020Derek NexusSarah Nexus
Derek and Sarah for Web 1.1 Installation GuideSeptember 2020pdf file
Integrating Knowledge Of Carcinogenicity Adverse Outcome Pathways (AOPs) With Experimental Data_EMGS Data Challenge 2020September 2020pdf fileKaptisDerek NexusVitic Nexus
Introducing the concept of virtual control groups into preclinical toxicology testingSeptember 2020ETOX
ICH M7 Expert Review Workshop: Resolving common prediction scenarios using automated arguments in Nexus 2.3 (Webinar Presentation Slides)September 2020pdf fileDerek NexusSarah Nexus
Setaria Product BrochureSeptember 2020pdf fileSetaria
Skin Sensitisation Evaluation GraphicSeptember 2020pdf fileDerek Nexus
Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity dataSeptember 2020Derek NexusSarah NexusVitic Nexus
Vitic PDE 2020.2.0 Release NotesAugust 2020pdf file

© 2020 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Thanks to QuestionPro's generosity, we now have survey software that powers our data intelligence.